Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Statistical issues in cost-effectiveness analysis.
Publication
, Journal Article
DeLong, ER; Simons, T
Published in: Am Heart J
May 1999
Duke Scholars
Published In
Am Heart J
DOI
ISSN
0002-8703
Publication Date
May 1999
Volume
137
Issue
5
Start / End Page
S47 / S50
Location
United States
Related Subject Headings
- Humans
- Health Care Costs
- Economics, Pharmaceutical
- Developed Countries
- Cost-Benefit Analysis
- Cardiovascular System & Hematology
- Cardiovascular Diseases
- Cardiovascular Agents
- 3201 Cardiovascular medicine and haematology
- 1117 Public Health and Health Services
Citation
APA
Chicago
ICMJE
MLA
NLM
DeLong, E. R., & Simons, T. (1999). Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Statistical issues in cost-effectiveness analysis. Am Heart J, 137(5), S47–S50. https://doi.org/10.1016/s0002-8703(99)70428-x
DeLong, E. R., and T. Simons. “Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Statistical issues in cost-effectiveness analysis.” Am Heart J 137, no. 5 (May 1999): S47–50. https://doi.org/10.1016/s0002-8703(99)70428-x.
DeLong ER, Simons T. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Statistical issues in cost-effectiveness analysis. Am Heart J. 1999 May;137(5):S47–50.
DeLong, E. R., and T. Simons. “Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Statistical issues in cost-effectiveness analysis.” Am Heart J, vol. 137, no. 5, May 1999, pp. S47–50. Pubmed, doi:10.1016/s0002-8703(99)70428-x.
DeLong ER, Simons T. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Statistical issues in cost-effectiveness analysis. Am Heart J. 1999 May;137(5):S47–S50.
Published In
Am Heart J
DOI
ISSN
0002-8703
Publication Date
May 1999
Volume
137
Issue
5
Start / End Page
S47 / S50
Location
United States
Related Subject Headings
- Humans
- Health Care Costs
- Economics, Pharmaceutical
- Developed Countries
- Cost-Benefit Analysis
- Cardiovascular System & Hematology
- Cardiovascular Diseases
- Cardiovascular Agents
- 3201 Cardiovascular medicine and haematology
- 1117 Public Health and Health Services